
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
Key Takeaways
- Dose-ranging phase 3 data showed placebo-adjusted body weight reductions of 9.3–16.3 percentage points at 48 weeks, with greatest efficacy at 4 mg and 6 mg (P < .001).
- Clinically meaningful response rates were robust: 68.1%–88.0% achieved ≥5% loss; at 6 mg, 75.4% achieved ≥10% and 44.4% achieved ≥20%, exceeding placebo.
Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.
Once-weekly subcutaneous ribupatide, an investigational dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, reduced body weight by up to 17.7% over 48 weeks in adults in China who are overweight or have
"Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks. Gastrointestinal adverse events were the most frequent tolerability findings," wrote the researchers of the study.
The multicenter, randomized, double-blind, placebo-controlled trial (
Up to 88% of Participants Lost at Least 5% of Body Weight
Least-squares mean body weight changes at week 48 were −10.7%, −16.4%, and −17.7% with ribupatide 2 mg, 4 mg, and 6 mg, respectively, compared with −1.4% with placebo. Placebo-adjusted differences were −9.3, −15.0, and −16.3 percentage points (P < .001 for all).
The proportion of participants achieving at least 5% weight reduction was 68.1%, 88.0%, and 85.7% across the 3 ribupatide doses vs 16.0% with placebo. At the 4-mg and 6-mg doses, 73.8% and 75.4% of participants, respectively, lost at least 10% of their body weight, and 37.1% and 44.4% lost at least 20%, compared with 9.2% and 3.5% with placebo. Weight loss had not clearly plateaued in either higher-dose group by week 48, the authors noted.
Compared with placebo, ribupatide also reduced waist circumference by 6.4 to 11.8 centimeters. In secondary analyses not adjusted for multiplicity, it lowered systolic blood pressure by 7.1 to 8.7 mm Hg and hemoglobin A1c by 0.32 to 0.47 percentage points.
Gastrointestinal Events Led Tolerability Findings
Gastrointestinal adverse events occurred in 47.9%, 58.2%, and 63.1% of participants receiving ribupatide 2 mg, 4 mg, and 6 mg, respectively, vs 23.1% with placebo, led by diarrhea, nausea, and vomiting. Most were mild to moderate and occurred primarily during dose escalation. Adverse events led to permanent treatment discontinuation in 1 or 2 participants per ribupatide group and none in the placebo group. Serious adverse events occurred in 1.4% to 5.0% of the ribupatide groups vs 5.6% with placebo. Papillary thyroid cancer was reported in 3 participants receiving ribupatide, which investigators assessed as probably unrelated to treatment; no medullary thyroid carcinoma or acute pancreatitis cases occurred.
Because participants were relatively young, the findings may not generalize to older adults, the authors noted.
Hengrui Has Filed for Approval in China
For context, the authors pointed to 17.5% weight loss with tirzepatide 15 mg at 52 weeks in the SURMOUNT-CN trial, while cautioning that cross-trial comparisons are descriptive only.
Jiangsu Hengrui Pharmaceuticals, which developed ribupatide (HRS9531), sponsored the trial. In November 2025, Hengrui and partner Kailera Therapeutics announced that China's National Medical Products Administration had accepted a marketing authorization application for the drug for chronic weight management in adults. Kailera is developing it outside Greater China as KAI-9531, with global phase 3 trials planned to evaluate maintenance doses including 8 mg and 10 mg.2
"The cardiometabolic benefits of ribupatide observed here are being further evaluated in an ongoing cardiovascular outcomes trial in individuals with atherosclerotic cardiovascular disease (
References
- Zhao L, Chen Y, Cheng Z, et al. Once-weekly ribupatide for weight loss in adults in China with overweight or obesity: the GEMINI-1 randomized clinical trial. JAMA. Published online November 15, 2026.
doi:10.1001/jama.2026.24796 - Hengrui Pharma and Kailera Therapeutics announce additional data from phase 3 obesity trial in China of dual GLP-1/GIP receptor agonist HRS9531. News release. Kailera Therapeutics. November 4, 2025. Accessed November 16, 2026.
https://investors.kailera.com/node/6651/pdf
Related to this article







